MAMMALIAN CELL TECHNOLOGY

Bioneer assists clients in the pre-clinical and early clinical phases with production of recombinant proteins in a variety of mammalian cell systems, with access to existing or development of novel functional assays based upon mammalian cells as well as general technology development, e.g. bioreactor evaluation, biobanking, and cell handling. In fact, we can support our clients in the entire process of bringing a novel biologic compound from the laboratory through pre-clinical evaluation for functionality and safety.

IMMUNE TARGETING

Bioneer offers evaluation of compounds using mainly three cell systems 1) Primary dendritic cells (human and murine) 2) Peripheral blood mononuclear cells (PBMCs) and 3) cell line based models. We provide services in our model systems in the discovery process (mainly evaluation of mechanism of action and immune modulation and suppression of specific inflammatory responses) as well as activities involved in the development process (mainly evaluation of safety of IV administered drugs, and assessment of potency).

PROTEIN MANUFACTURING

Bioneer addresses a client's needs for limited amounts of recombinant proteins, e.g. during the discovery phase and preclinical phase of biologics development.

DRUG DEVELOPMENT

Turning an active compound into a drug product

Pharmaceutical services, covering the field from lead identification to final formulation of the active compound, are provided by Bioneer:FARMA.

Bioneer:FARMA is a business unit of Bioneer established in collaboration with the Faculty of Pharmaceutical Sciences (FARMA), University of Copenhagen, Denmark.

BIOMARKERS

Bioneer offers a range of services related to the identification, validation and documentation of disease relevant biomarkers and drug targets. These services comprise a toolbox of molecular methods that will facilitate the pre-clinical development of both biomarkers, drug-targets and active compounds, which will be useful in diagnostic, prognostic, and therapeutic contexts, and, furthermore, serve as effective means to optimize clinical trial designs.

News:

2012-04-20:
Bedreinnovation.dk online fra den 17. april
BedreInnovation.dk- her giver de danske GTS-institutter mere end 100 forslag til investeringer i udvikling af nye teknologiske kocepter og serviceydelser, der skal gavne dansk erhvervsliv.
Read more
2012-04-12:
Bioneer facilitates export of Cell Factories
A Bioneer-initiated Innovation Consortium has led to the development by a Danish company of a novel bioreactor that can be used widely in the pharmaceutical industry
Read more
2012-04-12:
Article in Danish Biotech - April 2012 (in Danish)
Company profile of Bioneer A/S (in Danish)
Read more
2012-03-16:
Novel Dual Chamber Prefilled Syringe Technology
Novel Dual Chamber Prefilled Syringe developed by Bioneer employee.
Read more

Meet us at:

2012-05-07:
2012 BIO International Convention
Bioneer will participate in this year BIO International Convention in Boston, USA.
Read more
2012-05-07:
ILSI-Biomed 2012 in Tel Aviv, Israel
Bioneer will participate in this years ILSI-Biomed 2012 meeting in Tel Aviv, Israel from the 21-23 of May. 
Read more
2012-04-25:
EACR (European Association for Cancer Research)
Bioneer will participate in the annual meeting EACR-22 - from Basic Research to Personalised Cancer Treatment.
The meeting is held in Barcelina from 7-10 July 2012

Read more
2012-04-12:
BIO-Europe 2012 in Hamburg
meet Bioneer at BIO-Europe in Hamburg (Germany) from November 12.-14., 2012
Read more